Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
- 31 December 2004
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 18 (6) , 1105-1116
- https://doi.org/10.1016/j.bpg.2004.06.025
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Negative trials in nonalcoholic steatohepatitis: Why they happen and what they teach usHepatology, 2004
- Vitamin E therapy in patients with NASHHepatology, 2004
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡Hepatology, 2004
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneHepatology, 2003
- Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt ValuesHepatology, 2003
- Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic ConferenceHepatology, 2003
- Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitisJournal of Hepatology, 2003
- Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’Journal of Hepatology, 2001
- Persistent hyperaminotransferasemia resolving after weight reduction in obese childrenThe Journal of Pediatrics, 1994
- Hepatic effects of dietary weight loss in morbidly obese subjectsJournal of Hepatology, 1991